2 trial. Lancet 2003, 361:2099–2106.PubMedCrossRef 14. Monk BJ, Herzog TJ, Kaye SB, et al.: Trabectedin plus PLX4032 purchase pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010, 28:3107–3114.PubMedCrossRef 15. Vaage J, Donovan D, Mayhew E, Abra R, Huang A: Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993, 72:3671–3675.PubMedCrossRef 16. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al.: Pegylated liposomal Doxorubicin and Carboplatin compared
with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010, 28:3323–3329.PubMedCrossRef 17. Sugiyama T, Kamura T, Kigawa J, et al.: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. selleck products Cancer 2000, 88:2584–2589.PubMedCrossRef 18. T Enomoto CK, Yamasaki M, Sugita N, Otsuki Y, Ikegami H, Matsuzaki N, Yamada T, Wakimoto A, Murata Y: Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with
paclitaxel and carboplatin? Proc Am Soc Clin Oncol 2003, 22:477s. (abstr#1797) 19. Takakura S, Takano M, Takahashi F, et al.: Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer 2010, 20:240–247.PubMedCrossRef 20. Yoshino K, Enomoto T, Fujita M, Ueda Y, Kimura T, Kobayashi E, Tsutsui T, Kimura T: Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients. Int J Clin Oncol 2011, in press. 21. McGuire WP, Ozols RF: Chemotherapy of advanced ovarian
cancer. Semin Oncol 1998, 25:340–348.PubMed 22. Piccart MJ, Bertelsen K, James K, et al.: Randomized intergroup trial of cisplatin paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000, 92:699–708.PubMedCrossRef Glutamate dehydrogenase 23. Muggia FM, Braly PS, Brady MF, et al.: Phase III randomized study of 1 cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000, 18:106–115.PubMed 24. Armstrong DK, Bundy B, Wenzel L, et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34–43.PubMedCrossRef 25. Pignata S, Cannella L, Leopardo D, Pisano C, Bruni GS, Facchini G: Chemotherapy in epithelial ovarian cancer. Cancer Lett 2011, 303:73–83.PubMedCrossRef 26. Chan S, Friedrichs K, Noel D, et al.: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999, 17:2341–2354.PubMed 27.